Key result
Variants in SLCO1B1, ABCG2, and CYP2C9 are linked to increased statin-associated muscle symptoms and poor adherence.
Systematic Review
Answers are grounded in this paper and cite their sources.
Background Statins are one of the most prescribed medications in developed countries as the treatment of choice for reducing cholesterol and preventing cardiovascular diseases. However, a large proportion of patients experience adverse drug reactions, especially myotoxicity. Among the factors that influence the diversity of response, pharmacogenetics emerges as a relevant factor of influence in inter-individual differences in response to statins and can be useful in the prevention of adverse drug effects. Content A systematic review was performed of current knowledge of the influence of pharmacogenetics on the occurrence and prevention of statin-associated adverse reactions and clinical benefits of preemptive pharmacogenetics testing. Summary Genetic variants SLCO1B1 (rs4149056) for all statins; ABCG2 (rs2231142) for rosuvastatin; or CYP2C9 (rs1799853 and rs1057910) for fluvastatin are associated with an increase in muscle-related adverse effects and poor treatment adherence. Besides, various inhibitors of these transporters and biotransformation enzymes increase the systemic exposure of statins, thereby favoring the occurrence of adverse drug reactions. Outlook The clinical preemptive testing of this pharmacogenetic panel would largely prevent the incidence of adverse drug reactions. Standardized methods should be used for the identification of adverse effects and the performance and interpretation of genotyping test results. Standardization would allow to obtain more conclusive results about the association between SLCO1B1, ABCG and CYP2C9 variants and the occurrence of adverse drug reactions. As a result, more personalized recommendations could be established for each statin.
No takes yet. Share an insight, caveat, or question.
Medrano et al. (2023) conducted a systematic review in Statin-associated adverse drug reactions and myotoxicity. Genetic variants in SLCO1B1 (rs4149056), ABCG2 (rs2231142), and CYP2C9 (rs1799853 and rs1057910) during statin therapy was evaluated on Muscle-related adverse effects and poor treatment adherence. Genetic variants in SLCO1B1, ABCG2, and CYP2C9 are associated with increased statin-induced muscle-related adverse effects and poor treatment adherence.
Synapse has enriched 10 related papers. Consider them for comparative context: